Navigation Links
Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
Date:3/12/2008

VIENNA, Austria, March 12 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it will open a research facility in Cambridge, UK in addition to its headquarters in Vienna, Austria. The facility will be located at the Babraham Research Campus, home to a number of biotech companies and close to the Medical Research Council's Laboratory of Molecular Biology (LMB), the major center for antibody engineering in Europe.

The research site will start operations on April 15, 2008. The group located in Cambridge will mainly be responsible for lead generation based on the company's Modular Antibody Technology as well as, in the future, for research related to the conduct of collaborative studies between f-star and its pharma and biotech partners.

f-star's Cambridge site will start with a small group of highly experienced researchers in the field. The research group will be headed by Lutz Riechmann, a senior researcher with over 20 years of experience in antibody research in Sir Gregory Winter's group at the LMB.

"We are excited to open up a lab at the epicenter of Europe's antibody research and development community and to utilize the large pool of talent and experience concentrated in the Cambridge area," says Gottfried Himmler, CEO.

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb2) can be created.

f-star was found
'/>"/>

SOURCE f-star
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
3. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
4. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
5. Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer
6. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
7. Abbott Scientists Create One Molecule With Two Antibody Functions
8. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
9. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 HealthTronics, Inc ., ... radiology products and services, announced that a poster ... cryoablation) versus external beam radiotherapy (EBRT) is being ... Urological Association (MAAUA) Annual Meeting in Baltimore, Maryland ... of Cryosurgery and External Beam Radiation as Treatments ...
(Date:9/18/2014)... DALLAS , Sept. 18, 2014 /PRNewswire-iReach/ -- ... and China Acetic Acid Industry" and "2014 Deep ... Industry" reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... 2011 Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, ... (IND) to conduct a pivotal Phase 3 clinical trial ... nontuberculous mycobacteria (NTM) lung infections has been cleared by ... In 2010, Insmed initially submitted a regulatory filing ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... pivotal trial of pixantrone for the treatment of relapsed/refractory ... now open to patient enrollment. The trial, referred to ... a combination of pixantrone plus rituximab to a combination ...
... Driving value for customers is critical to organizational success across ... customer and an organization, there has to be an integrated ... succeed in the marketplace. Chris Bogan, CEO ... in this month,s special issue of PharmaVoice that the state ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 2Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 3Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 4Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Americans to undertake jaunts into the countryside each year could ... a century, according to new research. , Climate change could ... States as summer temperatures linger later into the year, Princeton ... Biogeography . For instance, the paper birch a popular ... could change color one to three weeks later by ...
(Date:9/18/2014)... -- Arizona turned its newborn screening program into a model ... earning it the first-ever Newborn Screening Quality Award from the ... Will Humble, M.P.H., Arizona,s Department of Health Services director, with ... established a policy of full transparency for the length of ... to the lab for analysis, and set a target of ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... has declined steadily in the last three decades. Although ... groups have shown some improvement, according to a recent ... the American Association for Cancer Research. "Our ... treatment, have resulted in profound gains, but these gains ...
... Barbara, Calif.) Scientists at UC Santa Barbara have found ... findings are published online in this week,s issue of the ... species differences in how they use the environment are key ... around us, but the importance of such niches have never ...
... the human brain reshapes itself to store this newfound knowledge. ... does that capacity to adapt reflect our risk for Alzheimer,s ... lives? Dr. Yaniv Assaf of Tel Aviv University,s Department ... effect of memory on brain structure. "With a specific MRI ...
Cached Biology News:Cancer mortality rates experience steady decline 2Scientists demonstrate importance of niche differences in biodiversity 2A window into the brain 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... 177 amino acid polypeptide sequence corresponding to ... Produced by activation of a recombinant ... coli periplasm. SPECIFIC ACTIVITY:The specific activity ... mU/mg, where 1 U is the activity ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
Biology Products: